Clinical trial NCT01297699: Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)
Official title: Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Thyroid Associated Ophthalmopathies
Graves´ Ophthalmopathy
Thyroid Eye Disease
Keywords: Graves´ orbitopathy
Graves´ ophthalmopathy
Thyroid eye disease
Thyroid-associated ophthalmopathy
Tocilizumab
EUGOGO
CAS
Lead sponsor: Hospital Clinico Universitario de Santiago
Sponsor class: OTHER
Collaborators: name: Fundación Ramón Domínguez
First posted: 2011-02-17
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose is to investigate tocilizumab administration in patients with moderately to severely or sight-threatening GO (Graves' ophthalmopathy) without response to treatment with corticoid intravenous pulses. Currently, these patients only have surgery as therapeutic alternative.

The principal aim of this study is to evaluate efficacy and safety of tocilizumab treatment in order to provide a better alternative to surgery for this patients.

Detailed description: Thyroid orbitopathy or Graves´orbitopathy (GO) is manifested for inflammation of the orbital and periorbital soft tissues. Ten percent of patients with GO will have long-term serious eye problems.

The cause of the GO is complex. Autoreactive T cells recognize an autoantigen, the TSH receptor present in the orbit and thyroid follicular cell, secrete cytokines (IL-6), which stimulate the fibroblasts to synthesize glycosaminoglycan, which draws liquid produce periorbital edema and muscle, causing exophthalmos.

This approach suggests that inhibition of IL-6 can be an effective treatment for this problem on the basis that tocilizumab specifically binds to the receptors of the IL-6, both soluble and membrane-bound. Tocilizumab has been shown to inhibit signaling mediated for IL-6Rm IL-6Rs.

Eligibility criteria: Principal Inclusion Criteria:

Patients diagnosed GO with CAS ≥ 4 and an index of severity, according EUGOGO guidelines, 1. moderately to severely or 2. sight-threatening GO, after receiving corticosteroid pulse treatment due to:

* Poor response to intravenous corticosteroid pulses Or
* Recurrence of the GO, after treatment with intravenous corticosteroids

Exclusion Criteria:

* Orbital decompression surgery needed immediately
* Active smoker
* Patients who could need treatment with radioactive iodine or thyroidectomy during the study
* Pregnant patient or patient who is planning to become pregnant during the study
* History of chronic recurrent or active infection
* History of intestinal ulceration or diverticulitis
* Patients with a history of chronic liver disease or liver disorders: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)
* History of HIV, hepatitis C or hepatitis B Positive
* Neutrophil count \< 0.5 × 109/L or a platelet count \< 50×103/μL
* Simultaneous use or contraindications to the use of immunosuppressive agents
* A treatment with another investigational drug within four weeks of selection or five half-lives of study drug
* Cardiovascular or cerebrovascular disease clinically significant
* Uncontrolled diabetes mellitus
* Use of corticosteroids during four weeks before to inclusion period
* History of reactions or anaphylactic allergic severe human monoclonal antibodies, humanized or murine
* Uncontrolled pathologies, whose exacerbations are treated with corticosteroids

Primary outcomes:
measure: Drug efficacy will be established as a decrease in CAS (clinical activity score) by 2 or more points in a scale of 10.
timeFrame: It will be measured before treatment (week -4 / 0), after treatment (week 16) and after the end of the follow-up (week 40).
Secondary outcomes:
measure: Clinical response of patients who respond to treatment with tocilizumab
timeFrame: It will be analyzed before treatment (week -4 / 0), after treatment (week 16) and once to follow up (week 40).
measure: Evaluate the patients quality of life associated with tocilizumab treatment, using SF-36
timeFrame: It will be analyzed before treatment (week -4 / 0), after treatment (week 16) and once to follow up (week 40).
measure: Determine time to recurrence during follow-up period
timeFrame: It is measured on a weeks-time scale assessed by the physician during patient follow-up visits.
measure: Safety as adverse events reported
timeFrame: 12 months
Other outcomes:
Locations:
city: Santiago de Compostela
country: Spain
facility: Hospital Clínico de Santiago
state: A Coruña
city: Barcelona
country: Spain
facility: Hospital Santa Creu i Sant Pau
city: Madrid
country: Spain
facility: Hospital Clínico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Santiago de Compostela
country: Spain
facility: Centro Oftalmológico Moreiras
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Valencia
country: Spain
facility: Hospital Universitario La Fe
city: Zaragoza
country: Spain
facility: Hospital Clínico Universitario Lozano Blesa
Study officials:
affiliation: Hospital Clínico de Santiago
name: Juan Jesús Gómez-Reino Carnota, MD, PhD
role: STUDY_CHAIR
affiliation: Centro Oftalmológico Moreiras
name: Jóse V. Pérez Moreiras, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: